CytomX Therapeutics, Inc. (CTMX) has announced positive interim results from its ongoing Phase 1 study of CX-2051, a masked, conditionally activated EpCAM-targeting antibody-drug conjugate or ADC, in patients with advanced, late-line colorectal cancer or CRC.
In parallel, the company also disclosed the pricing of a $100 million underwritten public offering of common stock to support continued research and development.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.